Glenmark Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 5/6
Glenmark Pharmaceuticals 의 총 주주 지분은 ₹84.5B 이고 총 부채는 ₹15.6B, 이는 부채 대 자기자본 비율을 18.5% 로 가져옵니다. 총자산과 총부채는 각각 ₹152.4B 및 ₹67.9B 입니다. Glenmark Pharmaceuticals 의 EBIT는 ₹17.8B 이며 이자보상배율은 4.9 입니다. ₹18.2B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
18.5%
부채 비율
₹15.62b
부채
| 이자 보상 비율 | 4.9x |
| 현금 | ₹18.20b |
| 주식 | ₹84.45b |
| 총 부채 | ₹67.90b |
| 총 자산 | ₹152.35b |
최근 재무 상태 업데이트
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20Recent updates
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now
Oct 26This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25재무 상태 분석
단기부채: GLENMARK 의 단기 자산 ( ₹90.3B )이 단기 부채( ₹61.8B ).
장기 부채: GLENMARK 의 단기 자산( ₹90.3B )이 장기 부채( ₹6.1B ).
부채 대 자본 내역 및 분석
부채 수준: GLENMARK 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: GLENMARK 의 부채 대 자기자본 비율은 지난 5년간 59.7% 에서 18.5% 로 감소했습니다.
부채 범위: GLENMARK 의 영업현금흐름이 마이너스이므로 부채가 제대로 상환되지 않습니다.
이자 보장: GLENMARK 의 부채에 대한 이자 지급은 EBIT( 4.9 x 적용 범위)로 잘 충당됩니다.